Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Inflectra / Remsima (infliximab biosimilar) by Year
Inflectra / Remsima (infliximab biosimilar) — U.S. reported YoY (%) (%)
Pfizer Inflectra / Remsima (infliximab biosimilar): 91.0% in FY2025, up 87.0 pts from a year earlier.
Latest, FY2025
91.0%
Period ended Dec 31, 2025
Change on a year earlier
+87.0 pts
4.0% in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below
Where the FY2025 figure comes from
“|| Inflectra | 646 | 509 | 27% | 27% | 511 | 268 | 91% | 134 | 241 | (44%) | (43%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Inflectra / Remsima (infliximab biosimilar) — U.S. reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 91.0% | +87.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 4.0% | -4.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 8.0% | -41.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2022 | Dec 31, 2022 | 49.0% | +21.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | 28.0% | -55.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗ |
| FY2020 | Dec 31, 2020 | 83.0% | +52.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312020xex99.htm, filed 2021-02-02) ↗ |
| FY2019 | Dec 31, 2019 | 31.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312019xex99.htm, filed 2020-01-28) ↗ |
Cite this data
StockData. (2026). Pfizer Inflectra / Remsima (infliximab biosimilar) (%), annual FY2019–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/inflectra-yoy-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.